178 related articles for article (PubMed ID: 36386154)
1. HAS2-Ezrin-ER axis plays a role in acquired antiestrogen resistance of ER-positive breast cancer.
Sun X; Tang F; Guo Q; Liu Y; He Y; Du Y; Gao F; Zhang G; Yang C
Front Pharmacol; 2022; 13():1031487. PubMed ID: 36386154
[TBL] [Abstract][Full Text] [Related]
2. The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance.
Suba Z
Drug Des Devel Ther; 2015; 9():4341-53. PubMed ID: 26273195
[TBL] [Abstract][Full Text] [Related]
3. The natural antisense transcript HAS2-AS1 regulates breast cancer cells aggressiveness independently from hyaluronan metabolism.
Parnigoni A; Caon I; Teo WX; Hua SH; Moretto P; Bartolini B; Viola M; Karousou E; Yip GW; Götte M; Heldin P; Passi A; Vigetti D
Matrix Biol; 2022 May; 109():140-161. PubMed ID: 35395387
[TBL] [Abstract][Full Text] [Related]
4. William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer.
Katzenellenbogen BS; Montano MM; Ekena K; Herman ME; McInerney EM
Breast Cancer Res Treat; 1997 May; 44(1):23-38. PubMed ID: 9164675
[TBL] [Abstract][Full Text] [Related]
5. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
[TBL] [Abstract][Full Text] [Related]
6. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
Zhang Y; Moerkens M; Ramaiahgari S; de Bont H; Price L; Meerman J; van de Water B
Breast Cancer Res; 2011 May; 13(3):R52. PubMed ID: 21595894
[TBL] [Abstract][Full Text] [Related]
7. HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells.
Alam MW; Persson CU; Reinbothe S; Kazi JU; Rönnstrand L; Wigerup C; Ditzel HJ; Lykkesfeldt AE; Påhlman S; Jögi A
Oncotarget; 2016 Mar; 7(10):11238-50. PubMed ID: 26849233
[TBL] [Abstract][Full Text] [Related]
8. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death.
Cook KL; Clarke PA; Parmar J; Hu R; Schwartz-Roberts JL; Abu-Asab M; Wärri A; Baumann WT; Clarke R
FASEB J; 2014 Sep; 28(9):3891-905. PubMed ID: 24858277
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
11. Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
Fox EM; Arteaga CL; Miller TW
Front Oncol; 2012; 2():145. PubMed ID: 23087906
[TBL] [Abstract][Full Text] [Related]
12. Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.
Suba Z
Recent Pat Anticancer Drug Discov; 2017; 12(2):136-147. PubMed ID: 28245776
[TBL] [Abstract][Full Text] [Related]
13. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
14. EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer.
Shajahan-Haq AN; Boca SM; Jin L; Bhuvaneshwar K; Gusev Y; Cheema AK; Demas DD; Raghavan KS; Michalek R; Madhavan S; Clarke R
Oncotarget; 2017 Nov; 8(57):96865-96884. PubMed ID: 29228577
[TBL] [Abstract][Full Text] [Related]
15. Tumor-suppressive functions of 4-MU on breast cancer cells of different ER status: Regulation of hyaluronan/HAS2/CD44 and specific matrix effectors.
Karalis TT; Heldin P; Vynios DH; Neill T; Buraschi S; Iozzo RV; Karamanos NK; Skandalis SS
Matrix Biol; 2019 May; 78-79():118-138. PubMed ID: 29673760
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
[TBL] [Abstract][Full Text] [Related]
17. ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.
Zhang J; Zhou C; Jiang H; Liang L; Shi W; Zhang Q; Sun P; Xiang R; Wang Y; Yang S
Cell Death Dis; 2017 Apr; 8(4):e2732. PubMed ID: 28383555
[TBL] [Abstract][Full Text] [Related]
18. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
Maynadier M; Basile I; Gallud A; Gary-Bobo M; Garcia M
Oncol Rep; 2016 Aug; 36(2):1127-34. PubMed ID: 27373750
[TBL] [Abstract][Full Text] [Related]
20. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
Long X; Fan M; Bigsby RM; Nephew KP
Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
